Objective: The use of anti psychotics to treat the behavioral symptoms of de mentia is associated with greater mortal ity. The authors examined the mortality risk of individual agents to augment the limited information on individual antipsy chotic risk.
tive risk=154, 95% confidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.S9-1.10), valproic acid and its derivatives (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-O.S0). Propensity stratified and propensity-weighted models as well as analyses controlling for site of care and medication dosage revealed sim ilar patterns. The mortality risk with halo peridol was highest in the first 30 days but decreased significantly and sharply there after. Among the other agents, mortality risk differences were most significant in the first 120 days and declined in the sub sequent 60 days during follow-up.
Conclusions: There may be differences in mortality risks among individual an tipsychotic agents used for treating pa tients with dementia. The use of valproic acid and its derivatives as alternative agents to address the neuropsychiatric symptoms of dementia may carry associ ated risks as well.
(Am J Psychiatry 2012; 169: [71] [72] [73] [74] [75] [76] [77] [78] [79] h e u.s. Food and Drug Administration (FDA) has not approved any drug for treating the neuropsychiatric symptoms of dementia. However, atypical antipsychot ics are commonly used for off-label treatment (1) . In April 2005, the FDA issued a black box warning that the use of atypical antipsychotics to treat behavioral disturbances in patients with dementia was associated with greater mor tality. Subsequent research reports confirmed the mortal ity risks associated with the use of both conventional and atypical antipsychotics to treat patients \·..,ith dementia (2) (3) (4) (5) . Another FDA black box warning for conventional antipsychotics followed in June 2008 (6) .
Information about mortality associated with individual antipsychotic agents in patients with dementia is lim ited. One study (7) found no significant mortality differ ences between olanzapine and risperidone. However, the number of deaths during this trial was small \\lith wide confidence intervals. In a 2005 meta-analysis of random ized placebo-controlled trials (2) , no greater risk of death was observed with any individual atypical antipsychotic; however, there may have been inadequate power to de tect significant differences after controlling for confound ing variables between trials. A study comparing the most frequently prescribed antipsychotic drugs in Canada (8) found higher 180-day mortality ratios for haloperidol and loxapine, but no difference between olanzapine and ris peridone. The most recent study (9) , using case-control methodology, found that patients with dementia taking haloperidol, olanzapine, and risperidone, but not que tiapine, had short-term increases in mortality compared with patients who were not taking these agents.
Large-scale comparisons of mortality with individual antipsychotic agents that control for important confound ers are currently lacking. Using multivariate and propen sity-scoring methods, we examined mortality risks in out patients with dementia in the 6 months after the start of treatment with a new antipsychotic, and we focused on the most commonly used individual agents for patients with dementia in the U.S. Department of Veterans Affairs (VA) health care system (risperidone, olanzapine, quetia pine, and haloperidol). Based on evidence from our earlier research that anticonvulsants had similar mortality risks to antipsychotics (3) and that there was a small but signifi cant increase in their use after the FDA black box warnings (10) , valproic acid and its derivatives were also included for comparison. and began outpatient treatment with a study medication after a l2-month "clean period" without exposure to antipsychotics or anticonvulsants. Over 87% of patients in the sample were treat ed \vith monotherapy during the 6-month follow-up. Given that switching to other antipsychotic agents might obscure risk pro files for individual antipsychotics. we restricted the final sample to these monotherapy patients. The final study sample included 33,604 patients.
Method

Study Cohort
Medications
We included risperidone, olanzapine. quetiapine, and haloper idol, as well as valproic acid and its derivatives (an anticonvulsant group commonly used as a second-line treatment strategy for the neuropsychiatric symptoms of dementia) in our study. Patients taking valproic acid and its derivatives (sodium valproate or di valproex) who also had seizure disorders (N=337) were excluded from the sample because their anticonvulsant use was less likely to be related to dementia.
Clinical Characteristics
Mortality data were obtained from the U.S. National Death In dex (National Center for Health Statistics, Hyattsville, Md.). Other variables included age, gender, ethnicity, marital status, and indi cators of psychiatric and medical comorbidity (the latter using a modified version of the Charlson comorbidities index [III based on 18 medical comorbidities [excluding demential in the year preceding new medication start). As delirium frequently occurs in patients 'vvith dementia and is an independent mortality risk factor (I2), and anti psychotics are often prescribed for delirium, we also assessed for the presence of a delirium diagnosis at the time of prescription. We used a coding scheme for acute confu sional states developed for a previous study (13) (10) , calendar time at the new medication start was included as a covariate. The model also in cluded number of hospitalizations and nursing home days in the year before the new medication was started and size, rurality, and academic affiliation of the VA medical center at which the medi cation was prescribed.
Statistical Analysis
We used descriptive statistics to categorize patient charac teristics by type of medication prescribed. A l80-day follow-up 72 ajp.psychiatryoniine.org period was chosen based on the duration of trials in the FDA's analysis and because it had been used in previous studies (S. 14). We examined medication exposure days in both intent-to-treat and exposure analyses. For the intent-to-treat analyses, exposure time was 6 months or time until death, whichever carne first. For the exposure analyses, exposure to a specific antipsychotic or valproic acid and its derivatives began on the date of the first filled prescription; exposure was censored at the end of the ex posure period, at 6 months, or at time of death, whichever came first. As in a previous study (2) , the exposure period continued for the duration of medication supply plus 30 days. Any gaps in prescription fills of less than 30 days were considered continued exposures. This accounts for some level of continued exposure and biological effect among patients who missed doses or used lower than prescribed doses.
For each of the medication types, mortality during the ISO-day follow-up was calculated per 100 person-years, and distribution of time to death since index prescription was estimated using the Kaplan.-Meier survival analysis method (15) .
A variety of approaches were used to deal ,,vith potential selec tion biases. Initially, we used multivariate analyses that included potential confounders available in administrative data. Addition ally. we used propensity-weighted and propensity-stratified meth ods. Both methods attempt to control for treatment by indication in observational studies by adjusting for the predicted probabil ity that a patient will receive a specific treatment conditional on the patient's baseline covariate values. The propensity-weighted analyses estimated hazard ratios using the Cox regression model, with observations weighted inversely by the propensity estimates obtained using multinomial models, permitting comparisons across multiple medications based on the one model (16) . Forthe propensity-stratified analyses, we made comparisons between pairs of medications, \vith each medication compared against risperidone. For each pairwise comparison, we estimated pro pensity scores using logistic regression. and we obtained hazard ratio estimates using the Cox regression model stratified by the estimated propensity quintiles. in both propensity-weighted and propensity-stratified methods. models used to obtain propensity scores were optimally fit to be highly predictable without consid eration for parsimony.
Our secondary analyses included examination of the site of care (psychiatric compared with nonpsychiatric setting) and adjustment for antipsychotic dosage, which was standardized to haloperidol equivalents (17) . After a visual inspection of the smoothed hazards revealed decreasing hazards over time for haloperidol, we also extended the Cox regression model to test for nonproportional hazards using logarithmically transformed time-by-medication indicator interaction terms. Upon finding significantly decreasing risks over time for haloperidol, we di vided the time since medication start into 30-day intervals, and we used a piece'A'.ise exponential model to compare relative risks between medications at different time intervals.
To confirm that our conclusion was not biased by including only those patients treated "vith monotherapy. we also performed a true intent-to-treat analysis in which patients who switched or augmented their initial medication were included. This analysis characterized this patient population by their exposure to the ini tial medication.
Last, we conducted two additional analyses to further examine mortality risk differences: 1) arl exploration ofwhether the larger proportion of Parkinson's disease patients in the quetiapine co hort may have resulted in a lower mortalily risk; and 2) an analy sis that further examined haloperidol's role as the agent with the highest mortality by comparing a number of key variables in hal operidol and risperidone users and individually matching these variables for each haloperidol patient with up to two risperidone patients. The crude 6-month mortality rates were as follows: hal days in the preceding year) than users of the other study operidol, 20.0%; olanzapine, 12.6%; risperidone, 12.5%; medications. A higher percentage of African American valproic acid and its derivatives, 9.8%; and quetiapine, patients were treated with haloperidol compared with 8.8% (X 2 =294.4, df=4, p<O.OOOl). The mortality rate rank the other agents. Those taking haloperidol were also sig ings were also consistent in the intent-to-treat and expo nificantly more likely to have used opioids or benzodiaz sure analyses (Table 2 ). epines and less likely to have used antidepressants during Multivariate adjustment and the propensity-weighted the year preceding the new antipsychotic start. Users of and propensity-stratified adjustments yielded similar re the various atypical agents had similar rates of medical sults. Adjusted relative risks (Table 3) averaged over a 180 and psychiatric comorbidities \\ith the exception of sig day period consistently revealed that haloperidol had the a All use and diagnostic data are based on 1 year prior to the initiation of the medication. b Includes schizophrenia and schizoaffective disorder, C Includes myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pUlmo nary disease, rheumatologic disease, peptic ulcer disease, cirrhosis, hepatic failure, diabetes mellitus, diabetes mellitus with complications, hemiplegia, chronic renal disease, malignant neoplasm, leukemia, lymphomas, metastatic solid tumor, and AIDS, highest mortality risk and quetiapine had the lowest risk.
Valproic acid and its derivatives showed a higher risk than quetiapine but, in all but one analysis, a risk lower than the other antipsychotics. Figure 1 shows the covariate-ad justed survival function by days of exposure.
Secondary Analyses
Site of care. Haloperidol users had the highest proportion of nonpsychiatnc visits associated with the prescription (77.6%) compared with users of the other medications (52.4%-57.8%). An analysis stratified by prescription lo cation produced results that were consistent with those from the main analyses, with haloperidol having the high est risk in both settings (propensity-stratified results: non- 90-120 days (p=0.02), each relative to the risperidone risk between 150 and 180 days. Mer 120 days, there were no longer significant mortality risk differences between any of the medications,
--------------------------------
Additional Sensitivity Analyses
Two additional analyses were performed to further understand mortality risk differences. First, we explored whether the larger proportion of patients with Parkinson's disease in the quetiapine cohort may have resulted in a lower mortality risk. Patients with Parkinson's disease tak ing quetiapine tended to receive lower quetiapine dosages and had less medical burden than patients without Par kinson's disease but were more likely to have depression. However, after covariate adjustment, patients with Parkin son's disease actually had higher mortality rates than pa tients without Parkinson's disease in the quetiapine cohort (relative risk=1.39, 95% CI=1.18-L64, p<O.OOl).
Second, we examined haloperidol's role as the agent with the highest mortality by comparing information about haloperidol and risperidone users after individu ajp.psychiatryonline.org ally matching each haloperidol patient with up to two risperidone patients. Variables included age, site of care (psychiatric or nonpsychiatric setting), race, and medical comorbidity (Charlson comorbidity index, presence of delirium diagnosis, and inpatient hospitalization in the preceding year). This analysis was based on 2,757 patients (1,056 patients taking haloperidol and 1,691 matched pa tients taking risperidone) and showed that haloperidol users were at a higher risk of mortality than risperidone users, with an adjusted relative risk of 1.45 (p=0.06) for the exposure analysis and 1.57 (p<O.OOl) for the intent-to treat analysis.
Finally, a true intent-to-treat analysis (which included patients who subsequently switched from their initial medication, N=3B,617) did not yield different conclusions from the main analyses: haloperidol users had the high est covariate-adjusted mortality rates (relative risk=1.50, 95% Cl=1.35-1.67) followed by olanzapine users (rela tive risk=1.02, 95% CI=0.92-1.12), risperidone users (ref erence), valproic acid and its derivatives users (relative risk=0.95, 95% CI=0.B2-1.10), and quetiapine users (rela tive risk=0.76, 95% Cl=0.70-0.B2).
Discussion
In this large national sample of outpatients with demen tia newly started on antipsychotic drugs or valproic acid and its derivatives, we examined differences in mortality among individual agents. Consistent across analyses was the finding that haloperidol had the highest mortality risk and quetiapine the lowest. The mortality risk for valproic acid and its derivatives, which were included as a nonanti psychotic comparison, was generally higher than the risk for quetiapine and similar to that for risperidone. Across all medications other than haloperidol, the mortality risk was found to be 1.5 times higher on average in the first 120 days than for the subsequent period; for haloperidol, ajp.psychiatryonline.org 76 the risk was highest in the first 30 days, and then it signifi cantly and sharply decreased.
Haloperidol's association with the highest mortality risks in this study is not surprising and confirms previ ous findings. Observational studies have reported that conventional antipsychotics as a group are associated with higher mortality risks than atypical antipsychot ics (B, 14) . In addition, Schneider and colleagues' meta analysis of atypical anti psychotics (2) showed haloperidol to have a higher risk of mortality compared with placebo (relative risk=1.6B) than did atypical antipsychotics (rela tive risk=1.54). The relationship between haloperidol and mortality may be confounded by selection issues and un derlying user characteristics, particularly given secular trends in which atypical anti psychotics largely replaced conventional antipsychotics in the 1990s (10, 1B, 19) . The shift from conventional to atypical antipsychotics during this period is thought to be because of efficacy evidence from early clinical trials, perceived safety advantages, and published expert consensus guidelines (20). In our sam ple, patients taking haloperidol were older, sicker (high est Charlson co morbidity index, most inpatient days, and highest concurrent delirium diagnoses)' and more likely to be African American than patients taking atypical antipsy chotics. After controlling for those confounding factors, the haloperidol-associated risks remained significant, al though it should be noted that the main risk of mortality with this agent appeared to be in the first month of treat ment, with a rapid decrease in mortality over time. The ma jority of haloperidol users (approximately 7B%) received their prescriptions at nonpsychiatric visits. This finding, paired with the likelihood of haloperidol being used for delirium in inpatient settings but possibly being counted on discharge in observational data as a "new prescription," might again suggest that the mortality difference could be influenced by unmeasured medical confounders such as unrecorded delirium episodes. However, our sensitivity analysis matched users of haloperidol to users of risperi done (chosen as the most relevant clinical comparison) using variables including age, race, medical comorbidities, and site of prescription (psychiatric or nonpsychiatric set ting) but did not corroborate this concern. Here, although only marginally significant because of the reduction in sample size from matching, haloperidol showed a greater mortality risk over risperidone (relative risk=1.45).
What about differences in risk among the atypical an tipsychotics? A recent case-control study (9) comparing information about antipsychotic users with nonusers found that quetiapine was not associated with short-term increases in mortality, while the other atypical antipsy chotics studied were. The study did not directly compare antipsychotics to each other to assess differential risk among these agents. Additionally, the comparison of an tipsychotic users to nonusers may have been problematic, as the underlying behavioral and frailty issues prompting medication use may be linked inextricably with mortality and may substantially overestimate the mortality risks of antipsychotics (21) . Using a variety of approaches to con trol for potential selection bias, our cohort study focused on head-to-head antipsychotic comparisons to examine differential risks among the atypical agents. We found that quetiapine had the lowest risk of mortal ity across' all analyses. Quetiapine is often prescribed in low dosages for its sedative/hypnotic properties; thus, we also performed analyses controlling for antipsychotic dos age. In these analyses as well, quetiapine was significantly associated with lower risk:. It is not clear why quetiapine would have a lower risk than the other atypical antipsy chotics, but it may be partially related to its receptor or side effect profile. A significantly higher proportion of patients taking quetiapine had Parkinson's disease; how ever, our sensitivity analyses did not indicate that this was a likely explanation for quetiapine's lower mortality risk:. An alternative explanation might be patient selection: perhaps those with milder dementia or behavioral dis turbances receive prescriptions for quetiapine. There is no rapid-acting form of quetiapine as there are for other atypical antipsychotics, so this agent is less likely to be used in urgent situations.
In most analyses, the mortality risk for valproic acid and its derivatives was higher than that for quetiapine but no different from that for risperidone or olanzapine. The use ofvalproic acid and its derivatives as an alternative to an tipsychotics in addressing neuropsychiatric symptoms of dementia may not be without other risks as well. Studies have linked anticonvulsant use in the elderly vvith fracture (22) , somnolence, and thrombocytopenia (23) . In addi tion, although valproic acid and its derivatives have been touted for behavioral stabilization and even potential neuroprotection, the evidence is lacking for such efficacy (24, 25) .
The greatest mortality risk for haloperidol was seen within the first 30 days; for the other medications, the risk was higher in the first 120 days than in the subsequent period. The exposure period for haloperidol was consider ably shorter than for the other agents, and the haloperidol result may be related in part to its use in older and sicker patients. A number of these patients may have started this agent during an inpatient stay for delirium or in nonpsy chiatric settings. There are several clinical implications of a greater mortality risk for atypical antipsychotics and val proic acid and its derivatives in the first 4 months of treat ment than in subsequent months. First, if these agents are prescribed, then they should be used in conjunction with a risk-benefit approach (26, 27) with consideration for the efficacy and safety evidence base for each agent (2-4, 6, 20, 26) . Second, patients should be monitored during the acute treatment period for adverse effects and reactions. Finally; periodic attempts at discontinuation should be made, particularly in light of the results from the Dementia Antipsychotic Withdrawal Trial (DART-AD). In DART-AD (5), the investigators randomly assigned pa tients with dementia to antipsychotic continuation (the majority taking risperidone [67%] or haloperidol [26%]) or antipsychotic discontinuation and placebo and observed a significantly higher mortality rate for patients continu ing antipsychotics. The difference in duration of mortality risk for antipsychotics between DART-AD (>12 months) and our study (:0;120 days) may be related to differences in exposure periods and study samples.
The use of administrative data for pharmacoepidemio logic research has several limitations. Prescription fills can be an imprecise measure of actual drug exposure as they may not reflect day-to-day usage. Data on dementia se verity were also lacking, although not accounting for this confounder may actually contribute to an underestima tion of the mortality risk of haloperidol (21) . Finally, while the large, integrated VA health system offers us the oppor tunity to examine pharmacoepidemiologic changes, the findings may not be completely generalizable. Consistent with the demographic characteristics of the VA patient population, the study cohort was primarily male. Howev er, our data and other national data have striking similari ties on many important variables that might affect provid er antipsychotic prescribing practices (e.g., race and the prevalence of key psychiatric and medical conditions [28, 29] ). Finally, the issue of concurrent delirium in dementia is also an important one, and as with other observational studies, we used diagnostic codes to denote the presence of delirium. Given the lack of recognition of delirium in ajp.psychiatryonline.org many cases, underdiagnosis is a problem; however,. we have no evidence to suggest that such underdiagnosis varies by antipsychotic agent. Despite these limitations, we used various analytic methods and our results consis tently indicated differences in mortality risks among in dividual antipsychotic agents. Further, the use ofvalproic acid and derivatives as alternative agents to address the neuropsychiatric symptoms of dementia may carry asso ciated risks as well.
